Cytori Announces New Annual Stockholders Meeting Date for June 27
June 19 2019 - 1:15PM
Cytori Therapeutics, Inc. (Nasdaq: CYTX) today announced that it
reconvened its annual meeting of stockholders on Tuesday, June 18,
2019 and adjourned the meeting until Thursday, June 27, 2019, at
9:00 a.m., Central Time. The annual meeting was adjourned to allow
the Company’s stockholders an additional opportunity to evaluate
Proposal 4, relating to the approval of a reverse stock split of
the Company’s common stock. Although more than 68% of the votes
cast were in favor of the reverse stock split (Proposal 4),
approval requires the affirmative vote of a majority of the
outstanding shares of common stock.
The annual meeting was adjourned until 9:00
a.m., Central Time, on June 27, 2019 at 4200 Marathon Blvd., Suite
200, Austin Texas 78756, the Company’s offices in Austin, Texas.
The record date for the annual meeting remains March 29, 2019.
Stockholders that have yet to vote are requested to do so prior to
the new June 27 meeting date and are encouraged to vote in favor of
the reverse stock split as outlined in the Company’s proxy
materials.
Stockholders who have previously sent in proxy
cards or given instructions to brokers do not need to re-cast their
votes unless they want to change their vote. Proxies previously
submitted in respect of the meeting will be voted at the adjourned
meeting unless properly revoked.
If stockholders have questions, need help voting
shares, or want to change a vote in favor of Proposal 4, please
call The Proxy Advisory Group, LLC, which is assisting the Company
in this matter at 1-888-557-7699 or 1-888-55PROXY.
The Company will postpone the corporate update
call originally scheduled for June 18, 2019 until after the
shareholder meeting on June 27th, 2019.
About Cytori
Therapeutics, Inc.
Cytori is developing, manufacturing, and
commercializing nanoparticle-delivered oncology drugs. Cytori is
focused on the liposomal encapsulation of anti-neoplastic
chemotherapy agents or other drugs which may enable the effective
delivery of the agents to target sites while reducing systemic
toxicity and improving pharmacokinetics. Cytori’s pipeline consists
of ATI-0918 pegylated liposomal doxorubicin hydrochloride for
breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s
sarcoma, a complex/hybrid generic drug, and ATI-1123 patented
albumin-stabilized pegylated liposomal docetaxel for multiple solid
tumors. For more information, please visit www.cytori.com.
Cytori Therapeutics, Inc.
Gary Titus, +1 (858) 458.0900ir@cytori.com
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytori Therapeutics (NASDAQ:CYTX)
Historical Stock Chart
From Sep 2023 to Sep 2024